For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

We are availabe to talk to you Monday - Friday 9am - 5pm

GDPR text - this is just a placeholder until correct text is inserted.

Have a member of our team call you back.

GDPR text - this is just a placeholder until correct text is inserted.

You can email us your enquiry by completing the form below.

Donec nisl risus, mattis ut, porttitor vitae, lobortis sagittis, lacus. Nullam neque ligula, congue at, fringilla at, consequat vitae, nulla. Nam ut felis. Curabitur imperdiet ligula a leo molestie malesuada. Praesent neque tortor, placerat accumsan, imperdiet non, iaculis at, mauris. In lacus quam, semper in, ullamcorper et, hendrerit id, pede. Nulla pretium sodales nunc.

Quisque augue quam, pulvinar in, accumsan et, pellentesque sed, ligula. Proin viverra, quam et aliquam molestie, turpis enim pellentesque eros, nec varius sem est id sapien. Aliquam at orci. Cras enim. Nam magna quam, elementum a, aliquet at, eleifend id, lacus. Donec et odio id quam laoreet suscipit.

Quisque ac ante. Aenean in neque. Suspendisse aliquet tincidunt pede. Duis mi. Morbi sapien. Cras posuere interdum nisl. Proin ac eros. Integer sit amet odio. Nullam nec velit dapibus augue condimentum egestas. Phasellus quis odio. Sed semper aliquet risus. Integer gravida vulputate sem. Praesent eu mauris. Fusce consequat congue dui. Vivamus quis metus non dui pellentesque tempor.

Davy Research

Uniphar

Upgrading forecasts and revisiting the investment case

Mar 24 2025, 07:00 GMT
Colin Grant
Company Report
17 page(s)

Sectors : Pharma and healthcare

Companies : Uniphar

Ratings and price correct at time of issue.

Uniphar

Closing Price: 267c
RATING 27/08/19
OUTPERFORM
PREVIOUS RATING N/A

Person's Name

Colin Grant

Analyst

DAVY VIEW

Following the recent share buyback, we are upgrading our Uniphar EPS forecasts by 3% in both 2025 and 2026. We upgraded by 2% in January. EPS could accelerate higher post completion of the group’s strategic investments. The 2028 EBITDA target is achievable and could drive the stock to €6.70, which in present value is close to our €5.00 price target.

View full article

Download full report with analyst certification and important disclosures

Mar 24 2025, 07:00 GMT